CA Patent

CA2971096A1 — A process for preparing halogenated azaindole compounds using pybrop

Assigned to ViiV Healthcare UK No 4 Ltd · Expires 2016-06-23 · 10y expired

What this patent protects

A process for preparing halogenated azaindole compounds makes use of a brominating agent PyBroP, together with a dehydrating agent BSA to enhance the selectivity and improve the yield of the final product which is a piperazine prodrug useful as an antiviral.

USPTO Abstract

A process for preparing halogenated azaindole compounds makes use of a brominating agent PyBroP, together with a dehydrating agent BSA to enhance the selectivity and improve the yield of the final product which is a piperazine prodrug useful as an antiviral.

Drugs covered by this patent

Patent Metadata

Patent number
CA2971096A1
Jurisdiction
CA
Classification
Expires
2016-06-23
Drug substance claim
No
Drug product claim
No
Assignee
ViiV Healthcare UK No 4 Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.